BioPharmSignal logoBioPharmSignal

Biotech News

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Harmony Biosciences (HRMY)Harmony BiosciencesConference / presentation

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20

Related news

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

HRMYHarmony Biosciences2026-06-11 12:05 EST

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

TNXPTonix Pharmaceuticals2026-09-02 11:00 EST

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

XENEXenon2026-09-03 20:01 EST

Xenon to Present at Wells Fargo Healthcare Conference

NBIXNeurocrine Biosciences2026-09-02 20:01 EST

Neurocrine Biosciences to Present at Upcoming Investor Conferences in September

GANXGain Therapeutics2026-08-25 11:00 EST

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference

ECORelectroCore2026-09-10 12:00 EST

electroCore to Participate at H.C. Wainwright Global Investment Conference

KTTAPasithea Therapeutics2026-09-03 20:05 EST

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences

CLNNClene Inc.2026-08-17 12:30 EST

Clene to Present at the Emerging Growth Conference

View all latest news

Harmony Biosciences

Sleep and Neurologic Disorders Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling. WAKIX Franchise WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the...

Recent company news

HRMYHarmony Biosciences2026-09-03 12:05 EST

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

HRMYHarmony Biosciences2026-08-27 12:05 EST

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

HRMYHarmony Biosciences2026-08-06 12:05 EST

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Stock data

Close
42.74 USD
Market cap
1.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States